RxDoctor Payments Data

Cathy Dahl, DO

Urogynecology and Reconstructive Pelvic Surgery · Lawrence, KSNPI 1871554998

Payments from drug & device makers

What this record shows

This record is dominated by education: $28,100 of the $32,531 with a category attached, or 86.4%. Intuitive Surgical accounts for 95.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $22,295 and has fallen 98.6% since, to $304 in 2025.

$32,531in general payments, 2019–2025

Across 86 payments — averaging $378.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$31K
  • Medtronic$341
  • Astellas Pharma US Inc$293
  • Caldera Medical, Inc$184
  • AbbVie$168
  • Hologic Sales And Service, LLC$145
  • plus $476 from 14 others

What the payments were for

  • Travel & lodging$8233%
  • Food & beverage$3,60711%
  • Education$28,10086%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$176,426
Medicare patients
299
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron93$66,655
GemtesaVibegron26$15,667
BotoxOnabotulinumtoxina20$13,031
Estradiol90$5,403
Trospium Chloride ErTrospium Chloride18$4,034
Solifenacin Succinate123$3,462
Darifenacin ErDarifenacin Hydrobromide16$3,216
Methenamine Hippurate27$1,903
Trospium Chloride33$1,159
Cephalexin97$983
Oxybutynin Chloride ErOxybutynin Chloride11$176
Gabapentin72$131
Oxycodone Hcl41$101
Ciprofloxacin Hcl19$76
Tramadol Hcl52$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$293$66,65593 claims
AbbVieBotox$168$13,03120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Kansason file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →